Diagnosis of Alzheimer's disease (AD), the most common form of dementia, involves neuropsychological testing, limited laboratory tests and brain imaging. Current therapeutic options for AD are symptomatic treatments that target dysfunctional neurotransmitters associated with the disorder. Recent research has focused on therapeutic strategies that inhibit the production and aggregation of amyloid beta protein (Aβ) in plaques and increase its clearance from the brain. Such strategies are likely to be most effective at pre-clinical stages of the disease, before widespread synaptic and neuronal loss occurs. Thus, there is a need for biomarkers that predict disease course and outcome and monitor disease progression and treatment efficacy. The development of such biomarkers for AD is critical to translating the efficacy of new therapies.
clinically by a decline in cognitive and functional ability and the development of behavioural and psychological symptoms. At a cellular level, it comprises degeneration of neurons and synapses, formation of amyloid plaques and intracellular neurofibrillary tangles. 1 Diagnosis of AD requires neuropsychological testing, limited laboratory tests and brain imaging. Since pathology generally precedes symptoms, AD is diagnosed after clinical onset of the disease, at which stage the patient is already suffering from cognitive defects such as mild cognitive impairment (MCI). 2 Moreover, the diagnostic accuracy of neurodegenerative disorders is low, ranging from 50 to 85%. 3 Current therapeutic options for AD are symptomatic treatments that target dysfunctional neurotransmitters associated with the disorder.
The only approved therapies are cholinesterase inhibitors and one N-methyl-D-aspartate receptor antagonist. Use of these agents is widespread and long-term; 4 however, they confer only moderate clinical effects in patients with mildly to moderately severe symptoms and do not affect the fundamental pathology of AD. 5 The majority of recent research has focused on therapeutic strategies that inhibit the production and aggregation of amyloid beta protein (Aβ) in plaques and increase its clearance from the brain. Such strategies are likely to be most effective at pre-clinical stages of the disease, before widespread synaptic and neuronal loss occurs. 1 Therefore, there is a need for biomarkers that predict the disease course and outcome and monitor disease progression and treatment efficacy. Biomarkers could also identify AD at an early stage and improve diagnosis. Biomarkers could also predict the disease course and outcome. Disorders such as diabetes have identifiable biomarkers that not only can be followed easily and repeatedly for diagnosis, but also can monitor therapeutic response. The development of such biomarkers for AD is critical to translating the efficacy of new therapies.
This article will outline the challenges and limitations of the current knowledge of AD biomarkers and discuss the validity of biomarker candidates as surrogate end-points in clinical trials.
Requirements of Biomarkers
Biomarkers have typically been selected by a 'candidate' approach in which a hypothesis about the disease is tested in order to identify a gene or molecular component of the disease process. 3 Established criteria exist for potential biomarkers of AD: they should reflect a neuropathological characteristic of AD and should be validated in patients with independently diagnosed AD pathology. Ideally, they should have sensitivity of ≥85% and specificity (to differentiate from controls and other forms of dementia) of ≥75%. 
Neurochemical Biomarkers
It is widely considered that the deposition of Aβ peptides in the brain is a key event in the pathogenesis of AD, and Aβ is secreted by cells, therefore it is a logical choice of biomarker. It is the main component of AD plaques and generally has a length of 42 or 40 amino acids (Aβ and Aβ 17 Very high sensitivity and specificity of 92 and 89%, respectively, have been reported using combined biomarker measurements. 18 Furthermore, clusters of biomarker levels have been correlated to cognitive profiles of AD patients. A study of 177 patients identified a subgroup displaying a distinct cognitive profile with severe impairment of memory, mental speed and executive functions. This was associated with low levels of Aβ and extremely high levels of T-tau and P-tau181, and showed no link to disease duration or severity. These findings have important implications: AD is a heterogeneous disease and future research is likely to focus on individualised therapy. 19 In order to be clinically meaningful, the intra-individual variation of biomarker levels over time must be low. A two-year study of 83 patients with MCI analysed levels of T-tau, P-tau181 and Aβ and found that intra-individual levels of these biomarkers were highly stable over this time. 20 In another study including 105 patients attending a memory clinic, the levels of Aβ 
Neuroimaging Techniques
In vivo neuroimaging techniques have become valuable candidate biomarkers in the determination of structural changes in the brain which aid diagnosis of AD. The two most widespread neuroimaging techniques are magnetic resonance imaging (MRI) and positron emission tomography (PET).
Are 
Combined Biomarker Approaches
Since combined measurements of CSF biomarkers improve accuracy in diagnosis of AD, combinations of neurochemical measurements and imaging parameters may achieve a more accurate early and differential diagnosis than individual methods.
Combined measurements of the CSF T-tau, Aβ 
Apolipoprotein E Genotype
The apolipoprotein E (APOE) β4 genotype is an important risk factor for AD and is associated with increased deposition of Aβ peptides and tau. 50, 51 Association between CSF biomarkers and APOE genotype is modified by age in both controls and AD patients, suggesting that cognitively healthy APOE β4 carriers are more prone to developing AD pathology with ageing. 52 This article does not discuss genetic parameters; however, the relevance of APOE should be mentioned, since it can affect activity or level of expression of biomarkers, and therefore is often included as a covariable in biomarker studies. A recent Dutch study investigated whether patient age affects the relationship between APOE genotype and the CSF biomarkers amyloid-β 1-42 , tau and P-tau 181 both in AD patients (n=302) and in healthy controls (n=174). 52 Among controls, older age and APOE β4
were associated with lower β 1-42 but higher tau and ptau-181 levels (p<0.05). Older carriers had higher levels than older non-carriers of tau and ptau-181, but this was not the case in younger controls. In AD patients, the strongest effect on β 1-42 was the APOE β4 genotype;
older carriers had lower β 1-42 than older non-carriers; but this was not the case in younger AD patients (p<0.05). The study indicated that cognitively unimpaired APOE β4 carriers are more likely to develop AD pathology as they become older and supported the existence of subtypes within the disease.
Surrogate End-points and Clinical Trials
Currently, the primary end-points for clinical trials of AD drugs are clinical outcomes. However, measurements of the severity of cognitive decline present difficulties as markers of progression.
Recent trials with disease-modifying treatments have shown negative results, including the amyloid-lowering agent tarenflurbil 53 and rosiglitazone. 54 Negative results could prove inefficacy of the drug studied, but may reflect inadequacies of the study designs:
poor choice of end-point, late initiation and/or short duration. 55 The ultimate validation of the use of biomarkers in AD will be achieved by clinical trials using imaging/biomarkers to select highrisk subjects and as surrogate end-points to assess therapeutic benefits. Multiple therapeutic interventions must result in changes in biomarkers that can be correlated to clinical outcomes.
Biomarkers will then be able to stand alone as surrogate end-points in clinical trials. Long-term monitoring of AD patients using biomarkers will be valuable in developing new treatments and, ultimately, preventing AD. n
